Tani Takashi, Arima Ryuji, Kaneko Tomohiro, Hayashi Hiroki, Tsuruta Kyoko, Shimizu Akira, Tsuruoka Shuichi
Department of Nephrology, Nippon Medical School l, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Department of Respiratory Care Medicine, Nippon Medical School l, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
CEN Case Rep. 2015 May;4(1):48-54. doi: 10.1007/s13730-014-0138-x. Epub 2014 Jul 22.
We describe a case of IgA nephropathy (IgAN) followed by pulmonary hemorrhage associated with Henoch-Schöenlein purpura (HSP) in an adult female. The patient had a history of renal insufficiency and persistent hematuria and proteinuria, without any extra-renal involvement. She was diagnosed with IgAN 7 years before the onset of HSP and had received immunosuppressive therapy for 6 years. One year after discontinuing oral prednisolone and mizoribine, she suffered a pulmonary hemorrhage. She presented with exacerbated urinary findings, and palpable purpura, resulting in the diagnosis of HSP. Intravenous pulse methylprednisolone followed by oral prednisolone (1 mg/kg/day) and a monthly intravenous cyclophosphamide pulse resolved the pulmonary hemorrhage. In a review of 36 HSP patients complicated with pulmonary hemorrhage, 27.8 % of the patients perished [Rajagopala et al., Semin Arthritis Rheum 42:391-400, 1]. While the most efficient therapeutic strategies for these patients have yet to be determined, we speculate that an aggressive therapy of pulse methylprednisolone combined with immunosuppression agents is likely to bring about the best outcome in cases with pathological conditions similar to our patient's. On the other hand, discontinuance of immunosuppressive therapy might have resulted in the aggravation of the disease, hence we should examine patients carefully not to miss the cue.
我们描述了一例成年女性IgA肾病(IgAN)继发与过敏性紫癜(HSP)相关的肺出血病例。该患者有肾功能不全、持续性血尿和蛋白尿病史,无任何肾外受累情况。她在HSP发病前7年被诊断为IgA肾病,并接受了6年的免疫抑制治疗。停用口服泼尼松龙和咪唑立宾1年后,她发生了肺出血。她出现了尿异常加重及可触及的紫癜,从而诊断为HSP。静脉注射甲泼尼龙冲击治疗,随后口服泼尼松龙(1mg/kg/天)及每月静脉注射环磷酰胺冲击治疗使肺出血得到缓解。在对36例合并肺出血的HSP患者的回顾中,27.8%的患者死亡[Rajagopala等人,《关节炎与风湿病杂志》42:391 - 400,1]。虽然这些患者最有效的治疗策略尚未确定,但我们推测,对于与我们患者病理情况相似的病例,积极的甲泼尼龙冲击治疗联合免疫抑制剂治疗可能会带来最佳结果。另一方面,免疫抑制治疗的中断可能导致了疾病的加重,因此我们应仔细检查患者以免错过线索。